Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lorazepam is a short-acting benzodiazepine medication primarily used to treat anxiety disorders, insomnia (especially when related to anxiety or situational stress), status epilepticus (continuous seizures), severe agitation, alcohol withdrawal symptoms, and chemotherapy-induced nausea and vomiting. It is also used as a pre-anesthetic agent and for sedation in mechanically ventilated patients. Lorazepam acts by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor in the central nervous system, resulting in sedative, anxiolytic, anticonvulsant, muscle relaxant, and amnesic effects. The drug was developed by Wyeth Pharmaceuticals and first introduced under the brand names Ativan and Temesta in 1977. Lorazepam is available as oral tablets/capsules (including extended-release forms), oral concentrate/solution, intravenous injection formulations, and topical/transdermal preparations[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lorazepam.